Uncategorized

Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform

Nine years after wowing the audience at the American Society of Clinical Oncology annual meeting with a CAR-T candidate that would become Carvykti—now the world’s most successful cell therapy—Legend Biotech’s scientific founder Frank Fan, M.D., Ph.D., is returning to the spotlight with an entirely new playbook.​Read More

Published

on

Nine years after wowing the audience at the American Society of Clinical Oncology annual meeting with a CAR-T candidate that would become Carvykti—now the world’s most successful cell therapy—Legend Biotech’s scientific founder Frank Fan, M.D., Ph.D., is returning to the spotlight with an entirely new playbook.​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version